Effect of prolonged hospitalization on fetal growth in threatened preterm labor

Maki Shibata, Takashi Kaji, Naoto Yonetani, Atsuko Yoshida, Eishi Sogawa, Kazuhisa Maeda, Minoru Irahara

Department of Obstetrics and Gynecology, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan

Abstract: Objective: We aimed to demonstrate the effect of prolonged hospitalization on fetal growth in cases of threatened preterm labor (TPL). Methods: In this retrospective cohort study, we included women who received prenatal care for TPL but delivered their child after 36 weeks of gestation. These were compared with a control group of healthy pregnant women and fetuses delivered at term. Fetal growth was compared using biparietal diameter, abdominal circumference (AC), femur length, and estimated fetal weight (EFW) assessed using ultrasonography at 18, 26, 30, and 36 weeks of gestation. Neonatal parameters at birth were also compared. Results: In total, we enrolled 228 control women and 114 women with TPL who were treated with hospitalization, including bed rest. The AC at 30 and 36 weeks of gestation and EFW at 36 weeks of gestation were smaller in women treated with bed rest than for normal pregnant women. The mean duration of pregnancy was shorter in the hospitalization group than in the control group. Neonatal weight, length, head circumference, and chest circumference at birth were smaller after prolonged hospitalization for TPL than after normal pregnancy. Conclusion: Prolonged hospitalization for threatened preterm labor is associated with impaired fetal growth, particularly AC. J. Med. Invest. 66: 153-156, February, 2019

Keywords: fetal growth, prolonged hospitalization, bed rest, threatened preterm labor

INTRODUCTION

Preterm birth, defined as birth prior to 37 weeks of gestation, affects 5%-18% of pregnancies and is the leading cause of neonatal mortality and morbidity (1-2). Inpatient bed rest is widely used to prevent preterm birth in women with threatened preterm labor (TPL) in Japan. Prolonged bed rest can induce muscle metabolism (3), increase bone turnover (4), thrombosis (5-6), weight loss (7), depressive symptoms (8-9), and other important symptoms in pregnant women. Based on not only its side effects, but also the lack of clear efficacy in the prevention of preterm delivery, the American Congress of Obstetricians Gynecologists (ACOG) states that bed rest is not prescribed routinely for preventing preterm birth (10).

In contrast, only a few studies have been conducted to evaluate the effect of prolonged hospitalization on fetuses. Maloni et al have reported that neonates born to mothers with bed rest weigh significantly less than the national mean (7). They, however, included pregnant women with various diseases, such as TPL, premature rupture of membranes, placenta previa, and abruptio. Therefore, the diseases that mothers had, and not bed rest, might have affected the neonatal weight.

Recently, we discovered that women treated with prolonged hospitalization for TPL had lower serum 25-hydroxyvitamin D (25 (OH)D) concentrations in the third trimester than those in the normal control group (11). Fetal bone growth and birth weight was lower among infants of mothers deficient in vitamin D than in their replete peers (12-14). Therefore, prolonged hospitalization during pregnancy for TPL was considered to affect fetal growth, particularly the bone length. However, fetal growth during maternal bed rest remains unclarified.

In this study, we aimed to elucidate the effect of prolonged hospitalization for TPL on fetal growth by assessing ultrasonographic in-utero parameters.

SUBJECTS AND METHODS

This retrospective study was conducted between January 2011 and December 2016 at Tokushima University hospital. The cohort comprised Japanese women with singleton pregnancies, those who received prenatal care, those who delivered after 36 weeks of gestation, and those who were admitted in the hospital for more than 28 consecutive days to manage TPL. Cases with regular obstetric uterine contractions and/or significant cervical changes (dilation and/or effacement) were diagnosed as TPL. They were admitted to reduce uterine contractions and prolong the pregnancy. Antepartum bed rest treatment with ambulation restricted only to bathroom privileges was prescribed. Intravenous ritodrine hydrochloride was administered as first-line tocolytic agent. Magnesium sulfate was used for women who continued to have symptomatic uterine contractions after the highest dose of ritodrine hydrochloride or for those who were not administered ritodrine hydrochloride because of adverse effects. The nutritional content of the meals provided to pregnant women admitted in the hospital included 626 mg of calcium, 1145 mg of phosphorus, 7 μg of vitamin D, and 2000 kcal/day on an average. These were compared with a control group of women who were not admitted for rest and who were matched by delivery season, maternal age, and pre-pregnancy body mass index. We excluded women who had multiple pregnan-
cies, carbohydrate metabolism disorders, hypertensive disorders of pregnancy, autoimmune disease, or receiving antenatal corticosteroid from the study cohort.

The following maternal parameters were collected: age at delivery, parity, height, body weight before pregnancy, body mass index before pregnancy, smoking status, season at delivery, weeks of pregnancy at delivery, and body weight gain during pregnancy. In addition, the following neonatal parameters were collected: birth weight, birth length, head circumference, chest circumference, sex, Apgar scores at 1 and 5 min, and pH and base excess of the umbilical artery at delivery. Fetal growth was measured and compared by the fetal biparietal diameter (BPD), abdominal circumference (AC), femur length (FL), and estimated fetal weight (EFW) assessed using ultrasonography at 18, 26, 30, and 36 weeks of gestation. EFW was calculated using the formula $1.07 \times BPD^3 + 0.30 \times AC^2 \times FL$ (15). The study was approved by our institutional review board.

All data are expressed as mean ± standard deviation. Statistical analysis of differences between groups was performed using the IBM SPSS software package and $P$ values < 0.05 were considered statistically significant.

RESULTS

In total, 114 cases and 228 matched controls were enrolled in this study. The maternal baseline characteristics and pregnancy outcomes are summarized in Table 1. There were no significant differences in maternal baseline characteristics between the two groups. However, the mean duration of pregnancy was significantly shorter (p < 0.01) in the hospitalization group (37.6 ± 1.4 weeks) than in the control group (39.0 ± 1.1 weeks). Maternal weight gain during pregnancy was also less in the hospitalization group (5.2 ± 9.1 kg) than in the control group (9.1 ± 10.1 kg). Women in the hospitalization group were admitted at 26.0 ± 4.0 weeks, and the duration of hospitalization was 68.4 ± 26.6 days. All pregnant women were treated with intravenous ritodrine hydrochloride and/or magnesium sulfate (ritodrine hydrochloride: 95 women, magnesium sulfate: 1 woman, ritodrine hydrochloride and magnesium sulfate: 18 women).

Figure 1 shows the results for fetal growth at 18, 26, 30, and 36 weeks of gestation. As shown, AC at 30 and 36 weeks of gestation and EFW at 36 weeks of gestation were significantly smaller in the hospitalization group than in the control group (24.74 ± 1.22 cm vs 25.23 ± 1.86 cm, p = 0.03; 29.44 ± 1.45 cm vs 30.05 ± 1.75 cm, p < 0.01; and 2441.39 ± 260.25 cm vs 2535.93 ± 294.12 cm, p < 0.01, respectively), whereas there were no differences in BPD and FL throughout the study period.

Overall, neonatal weight, length, head circumference, and chest circumference at delivery were significantly smaller in the hospitalization group than in the control group (p = 0.01, p = 0.01, p = 0.02, and p = 0.01, respectively). However, the Apgar scores, as well as the pH and base excess of the umbilical cord arteries, were comparable between the groups.

DISCUSSION

We demonstrated that AC and EFW in the third trimester of fetuses in women hospitalized for TPL were smaller than in normal pregnant women. To our knowledge, this is the first study showing adverse effect of prolonged hospitalization on in-utero fetal growth in TPL.

We previously reported that, compared with control groups,
serum 25(OH)D concentration are lower in mothers treated with hospitalization for TPL (11). Some authors have reported that maternal low 25(OH)D levels were associated with impaired fetal bone growth and birth weight (12-14,16). Consequently, we predicted that FL would be shorter and birth weight would be lesser in the hospitalization for TPL group than after standard care for normal pregnancies. However, there were no significant differences in either FL or BPD between the groups, whereas AC and EFW were smaller in the group treated with prolonged hospitalization. AC mainly represents soft tissue growth and is a more sensitive marker for fetal growth than is BPD (which mainly represents brain development) and FL (which represents skeletal development) (17). Ioannou et al. reported that fetal femoral volume and proximal metaphyseal diameter were positively associated with maternal 25(OH)D (18). Moreover, Vitamin D affects both bone resorption and formation (19), then the lack of vitamin D cause calcification failure of the bone (20). Based on the above, the width and/or quality of fetal bone might be more affected than length by low maternal Vitamin D.

Neonates delivered to women with prolonged hospitalization for TPL were smaller than those delivered to women in the control group, having smaller weights, lengths, head circumferences, and chest circumferences. It was difficult to say that prolonged hospitalization for TPL cause differences between neonates because neonates in the hospitalization group were born at an earlier gestational age than those in the control group. However, we followed fetal growth using ultrasound since before hospitalization not only at birth. There was no difference of fetal growth between the two groups before hospitalization or early during the hospitalization (18 and 26 weeks of gestation), but AC at 30 and 36 weeks of gestation and EFW at 36 weeks of gestation were smaller in the group with prolonged hospitalization. Therefore, we assumed that prolonged hospitalization, including bed rest, adversely affects fetal growth.

The possible cause other than low maternal vitamin D level for smaller AC, EFW, and smaller neonates for the hospitalization group is less maternal weight gain in the hospitalization group than in the control group. In the study conducted by Maloni et al., neonatal birth weight and maternal weight gain in pregnant women treated with bed rest for various diseases were significantly lower than their matched controls, including gestational age at birth (7). Birth weight is positively related to the maternal weight gain. Therefore, maternal weight gain itself might impair fetal growth.

The use of preterm labor treatment may also affect fetal growth in the hospitalization group. Ritodrine hydrochloride is a β-adrenergic stimulator, which thereby increases metabolism. Furthermore, magnesium sulfate prevents calcium influx into cells depolarization at the cell membrane. FDA states that magnesium sulfate may lead to low calcium levels and bone breaks (21), which could affect fetal growth.

This study has some limitations. First, the dietary intake of mothers in both groups was not established. In the TPL group individual dietary intake was not monitored, although a calculated meal was served. Women in the TPL group were less active, so their appetite might have reduced and caused insufficient food intake. Moreover, dietary intake in control group was not assessed. Second, there were no data about vitamin D intake or levels,

Table 2. Hospitalization data for women admitted with threatened preterm labor

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean ± standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age on admission (weeks)</td>
<td>26.0 ± 4.0</td>
</tr>
<tr>
<td>Duration of hospitalization</td>
<td>68.4 ± 26.6</td>
</tr>
<tr>
<td>Treatment contents</td>
<td></td>
</tr>
<tr>
<td>Intravenous ritodrine hydrochloride</td>
<td>95</td>
</tr>
<tr>
<td>Intravenous magnesium sulfate</td>
<td>1</td>
</tr>
<tr>
<td>Intravenous ritodrine hydrochloride + magnesium sulfate</td>
<td>18</td>
</tr>
</tbody>
</table>

Figure 1. Comparison of BPD, AC, FL, and EFW as fetal growth parameters between normal pregnant women and women treated with bed rest for threatened premature delivery

Fetal growth was assessed by the fetal biparietal diameter (BPD), abdominal circumference (AC), femur length (FL), and estimated fetal weight (EFW) at 18, 26, 30, and 36 weeks of gestation. Closed bar : pregnant women with bed rest for threatened premature delivery. *p < 0.05
which is important considering the knowledge that vitamin D levels affect fetal growth. Third, our study was retrospective and relatively small scale. Although AC and EFW were smaller in women with prolonged hospitalization for TPL than those in normal pregnant women, we do not know whether these differences affect neonatal prognosis, child development, or other risks. Low birth weight increases the risk of developmental disorders, short stature, impaired hearing, and epilepsy in childhood (22-23). Even after becoming an adult, it increases cardiovascular diseases, non-insulin-dependent diabetes, and hypertension (24-25). Thus, we need to examine long-term prognosis of neonates born to mothers with TPL.

In conclusion, our study shows that prolonged hospitalization for TPL is associated with an impaired growth, of AC and EFW in the third trimester. Treatment for TPL can adversely affect fetal growth.

CONFLICT OF INTEREST

There are no conflicts of interest to declare.

REFERENCES

21. FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. FDA Drug Safety Communications, 2013